Peking University Biologics

Company snapshot

Peking University Biologics is a one-stop biopharmaceutical CDMO professional organization with many years of biopharmaceutical scale-up, optimization, and technology transfer experience focusing on biologic drugs from gene development to CMC preparation, IND application, commercial manufacturing, BLA to commercialization. In 2021, we were the first leading biologics CDMO company to obtain the “Dr

• 15 active pipeline program(s) linked via ClinicalTrials.gov.
• 15 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Peking University Biologics. Not investment advice.

• What is Peking University Biologics?

  Peking University Third is a pharma organization headquartered in CN. Primary therapeutic focus areas include Clear Cell Renal Cell Carcinoma, Cushing s Syndrome, Esophageal Cancer, Prostate Cancer, Aged. NovaPharmaNews links 15 clinical program(s), 0 drug profile(s), and 0 paten

• Is Peking University Biologics publicly traded?

  Peking University Biologics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Peking University Biologics develop or market?

  We link 25 drug profile(s) where Peking University Biologics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/peking-university-third-hospital#company-drugs.

• What are the latest developments for Peking University Biologics?

  In the last 12 months our linked public records show 15 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Peking University Biologics focus on?

  Peking University Biologics focuses on Clear Cell Renal Cell Carcinoma, Cushing s Syndrome, Esophageal Cancer based on our analysis of their pipeline programs and drug development activities.